Yashoda Hospitals Researcher Yields New Data on Heart Failure (The Effectiveness and Tolerability of Switching Patients from Sacubitril/Valsartan, ARNI to Perindopril in Heart Failure with Reduced Ejection Fraction: Efficient Trial).

A study conducted at Yashoda Hospitals in Telangana, India, examined the effectiveness and tolerability of switching heart failure patients from the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan to perindopril. The study included 125 patients with heart failure with reduced ejection fraction (HFrEF), and data was collected on their New York Heart Association (NYHA) class, N-terminal pro hormone brain natriuretic peptide (NT-proBNP) levels, and left ventricular ejection fraction (LVEF) before and after the switch. The study found that the switch to perindopril was well tolerated and safe, with no significant changes in functional condition or NT-proBNP levels. There was a modest improvement in LVEF. The researchers noted that switching to perindopril is a less expensive option in India. [Extracted from the article]